Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A | P37088 | 17/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2288006 | 0.88 | SCNN1A (0.54) | SCNN1A | |
| Hydrochloric Acid SCHEMBL2288002 | 0.87 | SCNN1A (0.53) | SCNN1A | |
| SCHEMBL2292130 | 0.85 | SCNN1A (0.51) | SCNN1A | |
| SCHEMBL2333313 | 0.85 | SCNN1A (0.53) | SCNN1A | |
| SCHEMBL2328617 | 0.82 | SCNN1A (0.56) | SCNN1A | |
| SCHEMBL2286257 | 0.82 | SCNN1A (0.49) | SCNN1A | |
| SCHEMBL9913783 | 0.82 | SCNN1A (0.56) | SCNN1A | |
| SCHEMBL911558 | 0.80 | SCNN1A (0.54) | SCNN1A | |
| Hydrochloric Acid SCHEMBL2286228 | 0.80 | SCNN1A (0.47) | SCNN1A | |
| SCHEMBL937965 | 0.80 | SCNN1A (0.53) | SCNN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022210-B2 | 3-Aminopyrazine-2-carbonylguanidine derivatives; (4-{4-[N'-(3,5-Diamino-6-chloropyrazine-2-carbonyl)guanidino]butyl}phenoxy)acetic acid 2-piperidin-1-yl-ethyl ester; hydration of mucous membranes; respiratory system and gastrointestinal disorders; skin, eye and vaginal dryness; hypotensive agents; asthma | PARION SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-8008494-B2 | 2-(4-{4-[N'-(3,5-diamino-6-chloropyrazine-2-carbonyl)guanidino]-butyl}phenoxy)-N-(3-dimethylaminopropyl)acetamide dimethanesulfonate; promoting hydration of mucosal surfaces; Sjogren's disease, esophagitis, pneumonia, asthma, otitis, constipation, chronic diverticulitis, rhinosinusitis | PARION SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-7842697-B2 | Soluble amide and ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090324724-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090076273-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20080177072-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080171879-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-7399766-B2 | Soluble amide & ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20070021439-A1 | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20060040954-A1 | Soluble amide & ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171879-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | SCN2A, CACNA1B, HCN4 | SCNN1A 13/4885 |
| US-20060040954-A1 | Soluble amide & ester pyrazinoylguanidine sodium channel blockers | SCN2A, CACNA1B, HCN4 | SCNN1A 13/4885 |
| US-20090324724-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | SCN2A, CACNA1B, HCN4 | SCNN1A 13/4885 |
| US-20080177072-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | SCN2A, CACNA1B, HCN4 | SCNN1A 13/4885 |
| US-20070021439-A1 | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers | KCNN2, KCNN1, KCNN3 | SCNN1A 29/4885 |
| US-20090076273-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | SCN2A, CACNA1B, HCN4 | SCNN1A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.